Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease
The DOI matches its Crossref record; 282 of the 287 references it cites were found in a registry or an index.
Abstract
There is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes to its accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading enzymes, including neprilysin (NEP), insulin-degrading enzyme, and endothelin-converting enzyme reduce Aβ levels and protect against cognitive impairment in mouse models of AD. The activity of several Aβ-degrading enzymes rises with age and increases still further in AD, perhaps as a physiological response to minimize the buildup of Aβ. The age- and disease-related changes in expression of more recently recognized Aβ-degrading enzymes (e.g. NEP-2 and cathepsin B) remain to be investigated, and there is strong evidence that reduced NEP activity contributes to the development of cerebral amyloid angiopathy. Regardless of the role of Aβ-degrading enzymes in the development of AD, experimental data indicate that increasing the activity of these enzymes (NEP in particular) has therapeutic potential in AD, although targeting their delivery to the brain remains a major challenge. The most promising current approaches include the peripheral administration of agents that enhance the activity of Aβ-degrading enzymes and the direct intracerebral delivery of NEP by convection-enhanced delivery. In the longer term, genetic approaches to increasing the intracerebral expression of NEP or other Aβ-degrading enzymes may offer advantages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“through the production of various Aβ degrading enzymes, such as insulin-degrading enzyme (IDE), neprilysin (NEP), and MMP9, which may be secreted to degrade Aβ extracellularly [146–148]”
From Microglial dysfunction in brain aging and Alzheimer's disease (2014) · cites this paper as [146]
In the citing paper
“The Aβ degradation is ensured by some proteases, such as cathepsin and the insulin-degrading enzyme (IDE), which cleave the Aβ into smaller soluble fragments (Miners et al., 2011; Kurochkin et al., 2018).”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Miners et al., 2011
Citations
Cites
2 retracted
Items 201–282 of 282
β-Amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes
Deb, S., Wenjun Zhang, J., & Gottschall, P. E. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02344-8 · Cited by 81
Guan, H., Liu, Y., Daily, A., Police, S., Kim, M., Oddo, S., LaFerla, F. M., Pauly, J. R., Murphy, M. P., & Hersh, L. B. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21944 · Cited by 81 · cited 1×
“So too did transplantation of NEP-expressing leukocytes into 3 Tg AD mice, which had lower levels of soluble (30%) and plaque-associated AA (50%Y60%) and improved cognitive performance (254).”
BackgroundMiners, J. S., Van Helmond, Z., Kehoe, P. G., & Love, S. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00375.x · Cited by 80 · cited 2×
“Although it remains unproven that a decline in AAdegrading enzyme activity contributes to the accumulation of AA in AD (25, 26, 171), it is clear that overexpression of AA-degrading enzymes, neprilysin in particular, can reduce amyloid deposition and ameliorate cognitive decline in AD animal models (155, 161, 162).”
BackgroundMethodSelf-citationMorelli, L., Llovera, R., Gonzalez, S. A., Affranchino, J. L., Prelli, F., Frangione, B., Ghiso, J., & Castaño, E. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300276200 · Cited by 79 · cited 1×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
BackgroundZou, K., Maeda, T., Watanabe, A., Liu, J., Liu, S., Oba, R., Satoh, Y.-I., Komano, H., & Michikawa, M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.011437 · Cited by 76
Insulin-degrading Enzyme in Brain Microvessels
Morelli, L., Llovera, R. E., Mathov, I., Lue, L.-F., Frangione, B., Ghiso, J., & Castaño, E. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407283200 · Cited by 76 · cited 1×
“Neprilysin is expressed by CVSMCs within larger arterioles in the cerebral cortex and leptomeninges (80, 81), and ECE-1 (89) and IDE (116, 117) are expressed by endothelial cells.”
BackgroundEffects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen
Krauze, M. T., Saito, R., Noble, C. O., Bringas, J. R., Forsayeth, J., McKnight, T. R., Park, J. Y., & Bankiewicz, K. S. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.07.009 · Cited by 75 · cited 1×
“However, as research progressed to include the delivery of liposomes and viral vectors, it became clear that agents delivered by CED tended often to accumulate in close association with blood vessels and perivascular spaces (270, 271).”
BackgroundInsights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy
Love, S. (2009) · Frontiers in Bioscience · doi:10.2741/3567 · Cited by 75 · cited 1×
“The prevalence and severity of sporadic CAA increases with age and in AD (44, 182, 183).”
BackgroundSelf-citationGahete, M. D., Rubio, A., Durán-Prado, M., Avila, J., Luque, R. M., & Castaño, J. P. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1385 · Cited by 74 · cited 1×
“Reduction in SST (227) and SST receptor levels (228) may contribute to AA pathology in AD (229).”
BackgroundCirculating neprilysin clears brain amyloid
Liu, Y., Studzinski, C., Beckett, T., Murphy, M. P., Klein, R. L., & Hersh, L. B. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.05.014 · Cited by 74 · cited 2×
“Adenoassociated virus-mediated transfection of mouse NEP into the hind limb of 3 Tg-AD mice (harboring PS1M146V, hAPP(Swe), and tauP301L transgenes) produced a 60% reduction in soluble AA and 50% reduction in plaque deposits within the brain at 6 months (246).”
BackgroundIijima-Ando, K., Hearn, S. A., Granger, L., Shenton, C., Gatt, A., Chiang, H.-C., Hakker, I., Zhong, Y., & Iijima, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710509200 · Cited by 74 · cited 1×
“Overexpression of NEP by neurons in a Drosophila model of AD decreased AA1Y42 accumulation and neuronal loss but also led to an age-dependent axonal degeneration and shortened the lifespan of the flies (250), probably caused by the effects on physiological neuropeptide substrates of NEP, including enkephalin, substanc…”
BackgroundLeal, M. C., Dorfman, V. B., Gamba, A. F., Frangione, B., Wisniewski, T., Castaño, E. M., Sigurdsson, E. M., & Morelli, L. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000235853.70092.ba · Cited by 74 · cited 3×
“Interestingly, Leal et al (29) found that the increases in IDE protein level and activity were not mirrored by the mRNA level, which remained unchanged, suggesting that the increases were mediated by posttranslational modification.”
BackgroundKunwar, S., Sm, C., Prados, Berger, M. S., Sampson, J. H., Croteau, D. J., Sherman, J. W., Ay, G., Vs, S., Dul, J. L., et al. (2006) · PubMed · Cited by 74
Toropygin, I. Y., Kugaevskaya, E. V., Mirgorodskaya, O. A., Elisseeva, Y. E., Kozmin, Y. P., Popov, I. A., Nikolaev, E. N., Makarov, A. A., & Kozin, S. A. (2008) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3357 · Cited by 72
The Neprilysin Family in Health and Disease
Turner, A. J., Brown, C. D., Carson, J. A., & Barnes, K. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46826-3_25 · Cited by 71
Jung, S. S., Zhang, W., & Van Nostrand, W. E. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01745.x · Cited by 71
Insulin-Degrading Enzyme Exists Inside of Rat Liver Peroxisomes and Degrades Oxidized Proteins.
Morita, M., Kurochkin, I. V., Motojima, K., Goto, S., Takano, T., Okamura, S., Sato, R., Yokota, S., & Imanaka, T. (2000) · Cell Structure and Function · doi:10.1247/csf.25.309 · Cited by 70
CNS‐directed gene therapy for lysosomal storage diseases
Sands, M. S., & Haskins, M. E. (2008) · Acta Paediatrica · doi:10.1111/j.1651-2227.2008.00660.x · Cited by 69
Spencer, B., Marr, R. A., Gindi, R., Potkar, R., Michael, S., Adame, A., Rockenstein, E., Verma, I. M., & Masliah, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016575 · Cited by 69 · cited 1×
“Intraperitoneal injection of a lentivirus vectorexpressing NEP fused with the ApoB transport domain (allowing active transport across the blood-brain barrier) was associated with lower AA levels and a reversal of memory deficits in mThy1-hAPP751 mice (248).”
BackgroundAcyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide
Yamin, R., Zhao, C., O'Connor, P. B., McKee, A. C., & Abraham, C. R. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-33 · Cited by 68 · cited 5×
“The levels of several other candidate AA-degrading proteases, namely, ECE-2 (31), MMP-2 and MMP-9 (64, 173), CTSB (32, 174, 175), and APEH (70), were reported to be elevated in AD; however, in other studies, the concentrations and activities of MMP-2, MMP-3, MMP-9, and plasmin were not increased (120, 124).”
BackgroundInfluentialDegradation of Alzheimerʼs β-amyloid protein by human cathepsin D
McDermott, J. R., & Gibson, A. M. (1996) · NeuroReport · doi:10.1097/00001756-199609020-00021 · Cited by 67 · cited 1×
“Cathepsins S, D, and B were reported to participate in the intracellular degradation of AA peptides in human and rat brains (32, 221, 222).”
BackgroundGoldfine, I. D., Williams, J. A., Bailey, A. C., Wong, K. Y., Iwamoto, Y., Yokono, K., Baba, S., & Roth, R. A. (1984) · Diabetes · doi:10.2337/diab.33.1.64 · Cited by 67
Mohajeri, M. H., Wollmer, M. A., & Nitsch, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202899200 · Cited by 67 · cited 1×
“Further support comes from the rise in IDE level (29), tissue plasminogen activator and urokinase plasminogen activator activity (28), and MMP-2 and -9 activity (27) in aged hAPP mice and the dosedependent induction of neuronal NEP in hAPP mice given intracerebral injections of synthetic fibrillar AA (177, 178).”
BackgroundMechanisms of Cerebrovascular Amyloid Deposition: Lessons from Mouse Models
BURGERMEISTER, P., CALHOUN, M. E., WINKLER, D. T., & JUCKER, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06381.x · Cited by 66
Poirier, R., Wolfer, D. P., Welzl, H., Tracy, J., Galsworthy, M. J., Nitsch, R. M., & Mohajeri, M. H. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.003 · Cited by 65 · cited 3×
“Overexpression of human NEP (È8-fold increase) in hAPP (Swe/Ind) transgenic mice markedly reduced cerebral AA, largely preventing plaque formation, and significantly improved life expectancy (47, 155).”
BackgroundDuckworth, W. C., Bennett, R. G., & Hamel, F. G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31430-8 · Cited by 61
Degradation of Amyloid β Protein by Purified Myelin Basic Protein
Liao, M.-C., Ahmed, M., Smith, S. O., & Van Nostrand, W. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.050856 · Cited by 61 · cited 2×
“N, neprilysin (45Y49); E, endothelin-converting enzyme (49Y51); I, insulindegrading enzyme (47, 48, 52Y55); A, angiotensin-converting enzyme (56Y60); M2, matrix metalloproteinase 2 (61Y63); M9, matrix metalloproteinase 9 (64, 65); P, plasmin (28, 45, 51, 66, 67); C, CTSB (66); Mt1, membrane-type metalloproteinase 1 (6…”
BackgroundConvection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease
Lonser, R. R., Walbridge, S., Murray, G. J., Aizenberg, M. R., Vortmeyer, A. O., Aerts, J. M. F. G., Brady, R. O., & Oldfield, E. H. (2005) · Annals of Neurology · doi:10.1002/ana.20444 · Cited by 57 · cited 1×
“It was also used for enzyme replacement in preclinical models of Gaucher disease in which preservation of enzyme function after CED was later demonstrated (266, 267).”
MethodVepsäläinen, S., Hiltunen, M., Helisalmi, S., Wang, J., van Groen, T., Tanila, H., & Soininen, H. S. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.04.025 · Cited by 56 · cited 1×
“Vepsalainen et al (179) reported that the earliest disparity in NEP and IDE levels between hAPP and wild-type control mice coincided with the onset of AA1Y40 and AA1Y42 deposition.”
BackgroundYang, L., Xu, S., Liu, C., & Su, Z. (2009) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-009-3121-1 · Cited by 55 · cited 1×
“9-fold increase in NEP gene transcription were observed in SK-N-SH cells transfected with hAPP (Swe) after incubation by gensenoside Rg3, a major component of ginseng (242).”
MethodNumata, K., & Kaplan, D. L. (2010) · Biochemistry · doi:10.1021/bi902134p · Cited by 55 · cited 6×
“The cleavage products were also morphologically distinct, protease XIV cleavage products resembling oligomers (morphologically distinct from AA fibrils) (139), and those from >-chymotrypsin degradation having fibrillar characteristics.”
BackgroundInfluentialMisiti, F., Sampaolese, B., Pezzotti, M., Marini, S., Coletta, M., CECCARELLI, L., Giardina, B., & Clementi, M. E. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.01.001 · Cited by 55 · cited 1×
“AA peptide fragments AA25Y35 (140) and AA22Y35 (141) also have similar in vitro neurotoxicity and aggregation profiles to their full-length AA counterparts (142) and AA17Y20 and AA30Y35 peptide fragments, which themselves do not self-aggregate spontaneously promote the aggregation and neurotoxicity of full-length AA1Y…”
BackgroundCharacterization of Endothelin-converting Enzyme-2
Mzhavia, N., Pan, H., Che, F.-Y., Fricker, L. D., & Devi, L. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211242200 · Cited by 54
Eisele, Y. S., Baumann, M., Klebl, B., Nordhammer, C., Jucker, M., & Kilger, E. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-01-0035 · Cited by 54 · cited 1×
“The tyrosine kinase inhibitor, imatinib mesilate (Gleevec), increases APP intracellular domain and NEP and lowers cellular AA (235).”
BackgroundBarnes, K., Doherty, S., & Turner, A. J. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64041826.x · Cited by 54
Mouri, A., Zou, L.-B., Iwata, N., Saido, T. C., Wang, D., Wang, M., Noda, Y., & Nabeshima, T. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.10.014 · Cited by 53
Hüll, M., Müksch, B., Akundi, R. S., Waschbisch, A., Hoozemans, J. J. M., Veerhuis, R., & Fiebich, B. L. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.08.013 · Cited by 53 · cited 2×
“AA peptide fragments AA25Y35 (140) and AA22Y35 (141) also have similar in vitro neurotoxicity and aggregation profiles to their full-length AA counterparts (142) and AA17Y20 and AA30Y35 peptide fragments, which themselves do not self-aggregate spontaneously promote the aggregation and neurotoxicity of full-length AA1Y…”
BackgroundNostrand, W. E. V., Davis-Salinas, J., & Saporito-Irwin, S. M. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34436.x · Cited by 50 · cited 13×
“Heneka et al (209) reported that the addition of noradrenaline to cultures of microglia exposed to fibrillar AA1Y42 suppressed cytokine and chemokine production and promoted cell migration and phagocytosis of AA.”
BackgroundInfluentialLynch, J. A., George, A., Eisenhauer, P. B., Conn, K. J., Gao, W., Carreras, I., Wells, J. M., McKee, A. C., Ullman, M. D., & Fine, R. E. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20809 · Cited by 49 · cited 1×
“Neprilysin is expressed by CVSMCs within larger arterioles in the cerebral cortex and leptomeninges (80, 81), and ECE-1 (89) and IDE (116, 117) are expressed by endothelial cells.”
BackgroundMiners, J. S., Kehoe, P. G., & Love, S. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00486.x · Cited by 48 · cited 3×
“The best characterized of these are illustrated in this diagram: enzymatic degradation within the brain parenchyma (17Y19); perivascular drainage of AA along basement membranes to cervical lymph nodes and into the cerebrospinal fluid (9, 10, 20); transport across vessel walls into the circulation, mediated by binding…”
BackgroundSelf-citationSun, X., Becker, M., Pankow, K., Krause, E., Ringling, M., Beyermann, M., Maul, B., Walther, T., & Siems, W. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.058 · Cited by 48
Hernandez-Guillamon, M., Mawhirt, S., Fossati, S., Blais, S., Pares, M., Penalba, A., Boada, M., Couraud, P.-O., Neubert, T. A., Montaner, J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.135228 · Cited by 48
Aguado‐Llera, D., Arilla‐Ferreiro, E., Campos‐Barros, A., Puebla‐Jiménez, L., & Barrios, V. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02889.x · Cited by 47 · cited 1×
“Infusion of AA resulted in impaired SST signaling (230) and reduction in NEP (231).”
BackgroundAutocatalytic Cleavage of Myelin Basic Protein: An Alternative to Molecular Mimicry
D’Souza, C. A., Wood, D. D., She, Y., & Moscarello, M. A. (2005) · Biochemistry · doi:10.1021/bi051152f · Cited by 47
Plasminogen and plasmin in Alzheimer's disease
Barker, R. M., Love, S., & Kehoe, P. G. (2010) · Brain Research · doi:10.1016/j.brainres.2010.08.025 · Cited by 46 · cited 1×
“The levels of several other candidate AA-degrading proteases, namely, ECE-2 (31), MMP-2 and MMP-9 (64, 173), CTSB (32, 174, 175), and APEH (70), were reported to be elevated in AD; however, in other studies, the concentrations and activities of MMP-2, MMP-3, MMP-9, and plasmin were not increased (120, 124).”
BackgroundSelf-citationZou, L.-B., Mouri, A., Iwata, N., Saido, T. C., Wang, D., Wang, M., Mizoguchi, H., Noda, Y., & Nabeshima, T. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095687 · Cited by 45 · cited 1×
“Infusion of the NEP inhibitor thiorphan in rats was also associated with impairment of cognitive performance (153, 154).”
BackgroundCell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin
Rose, C., VOISIN, S., Claude, G. R. O. S., Schwartz, J.-C., & Ouimet, T. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3630697 · Cited by 45
ACE variants and association with brain Aβ levels in Alzheimer's disease.
Miners, J. S., Helmond, Z. V., Raiker, M., Love, S., & Kehoe, P. G. (2010) · PubMed Central · Cited by 43
Self-citationMiners, J. S., Verbeek, M. M., Rikkert, M. G. M. O., Kehoe, P. G., & Love, S. (2007) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2007.08.012 · Cited by 43 · cited 3×
“We have optimized several immunocapture-based fluorogenic assays of AA-degrading enzyme activity for use on postmortem brain tissue and CSF (169, 170).”
MethodSelf-citationVan Helmond, Z., Miners, J. S., Kehoe, P. G., & Love, S. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00321.x · Cited by 43
Self-citationAnti‐amyloid activity of neprilysin in plaque‐bearing mouse models of Alzheimer's disease
Mohajeri, M. H., Kuehnle, K., Li, H., Poirier, R., Tracy, J., & Nitsch, R. M. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00169-3 · Cited by 43 · cited 1×
“Further support comes from the rise in IDE level (29), tissue plasminogen activator and urokinase plasminogen activator activity (28), and MMP-2 and -9 activity (27) in aged hAPP mice and the dosedependent induction of neuronal NEP in hAPP mice given intracerebral injections of synthetic fibrillar AA (177, 178).”
BackgroundZirzow, G. C., Sanchez, O. A., Murray, G. J., Brady, R. O., & Oldfield, E. H. (1999) · Neurochemical Research · doi:10.1023/a:1022578424693 · Cited by 42 · cited 1×
“It was also used for enzyme replacement in preclinical models of Gaucher disease in which preservation of enzyme function after CED was later demonstrated (266, 267).”
MethodNEUROLOGICAL INFECTION AND INFLAMMATION
Bone, I. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.034249 · Cited by 42
Yamin, R., Bagchi, S., Hildebrant, R., Scaloni, A., Widom, R. L., & Abraham, C. R. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04251.x · Cited by 40 · cited 1×
“N, neprilysin (45Y49); E, endothelin-converting enzyme (49Y51); I, insulindegrading enzyme (47, 48, 52Y55); A, angiotensin-converting enzyme (56Y60); M2, matrix metalloproteinase 2 (61Y63); M9, matrix metalloproteinase 9 (64, 65); P, plasmin (28, 45, 51, 66, 67); C, CTSB (66); Mt1, membrane-type metalloproteinase 1 (6…”
Improved Learning and Memory in Aged Mice Deficient in Amyloid β-Degrading Neutral Endopeptidase
Walther, T., Albrecht, D., Becker, M., Schubert, M., Kouznetsova, E., Wiesner, B., Maul, B., Schliebs, R., Grecksch, G., Furkert, J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004590 · Cited by 40 · cited 1×
“Overexpression of NEP by neurons in a Drosophila model of AD decreased AA1Y42 accumulation and neuronal loss but also led to an age-dependent axonal degeneration and shortened the lifespan of the flies (250), probably caused by the effects on physiological neuropeptide substrates of NEP, including enkephalin, substanc…”
BackgroundPalmer, J. C., Kehoe, P. G., & Love, S. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01084.x · Cited by 38 · cited 5×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
BackgroundInfluentialSelf-citationPlasmin deficiency does not alter endogenous murine amyloid beta levels in mice
Tucker, H. M., Simpson, J. F., Kihiko‐Ehmann, M., Younkin, L. H., McGillis, J. P., Younkin, S. G., Degen, J. L., & Estus, S. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.07.011 · Cited by 38 · cited 1×
“Genetic knockout of plasmin, urokinase plasminogen activator, or tissue plasminogen activator, other candidate proteases that cleave AA in vitro, did not result in alterations in endogenous AA (148), nor did the absence of ACE alter steadystate levels of AA (149, 150).”
BackgroundEffects of HNE‐modification induced by Aβ on neprilysin expression and activity in SH‐SY5Y cells
Wang, R., Wang, S., Malter, J. S., & Wang, D. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05855.x · Cited by 38 · cited 1×
“This hypothesis is supported by a large number of reports of induction of proteases, including NEP (176), ECE (30), ACE (33), ECE-2 (31), IDE (29), MMP-2, -3, and -9 (34Y36), and CTSB (32), after exposure to AA, particularly fibrillar forms.”
BackgroundBaig, S., Kehoe, P. G., & Love, S. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00897.x · Cited by 38 · cited 1×
“The levels of several other candidate AA-degrading proteases, namely, ECE-2 (31), MMP-2 and MMP-9 (64, 173), CTSB (32, 174, 175), and APEH (70), were reported to be elevated in AD; however, in other studies, the concentrations and activities of MMP-2, MMP-3, MMP-9, and plasmin were not increased (120, 124).”
BackgroundSelf-citationAyoub, S., & Melzig, M. F. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.4.0009 · Cited by 38 · cited 1×
“Other substances reported to increase NEP activity include green tea extracts (243) and red wine (244).”
BackgroundAkiyama, H., Shii, K., Yokono, K., Yonezawa, K., Sato, S., Watanabe, K., & Baba, S. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(88)80583-7 · Cited by 36
Whyteside, A. R., & Turner, A. J. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.05.046 · Cited by 36
Controlled dissemination of AAV vectors in the primate brain
Varenika, V., Kells, A. P., Valles, F., Hadaczek, P., Forsayeth, J., & Bankiewicz, K. S. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17511-8 · Cited by 33 · cited 1×
“However, as research progressed to include the delivery of liposomes and viral vectors, it became clear that agents delivered by CED tended often to accumulate in close association with blood vessels and perivascular spaces (270, 271).”
BackgroundHuman membrane metallo-endopeptidase-like protein degrades both beta-amyloid 42 and beta-amyloid 40
Huang, J., Bruno, A. M., Patel, C. A., Huynh, A. M., Philibert, K., Glucksman, M. J., & Marr, R. A. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.05.006 · Cited by 33
Misbin, R. I., & Almira, E. C. (1989) · Diabetes · doi:10.2337/diab.38.2.152 · Cited by 33
Activated isoforms of MMP-2 are induced in U87 human glioma cells in response to β-amyloid peptide
Deb, S., Zhang, J. W., & Gottschall, P. E. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990101)55:1<44::aid-jnr6>3.0.co;2-g · Cited by 33
Cheifetz, S., Boggs, J. M., & Moscarello, M. A. (1985) · Biochemistry · doi:10.1021/bi00340a032 · Cited by 31
Burgos‐Ramos, E., Martos‐Moreno, G. Á., López, M. G., Herranz, R., Aguado‐Llera, D., Egea, J., Frechilla, D., Cenarruzabeitia, E., León, R., Arilla‐Ferreiro, E., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05980.x · Cited by 31 · cited 1×
“These abnormalities were prevented by administration of minocycline (231) and insulin-like growth factor 1 (232), suggesting that enhancement of SST signaling might be used to increase NEP activity.”
BackgroundDavenport, A. P., & Kuc, R. E. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200036051-00006 · Cited by 31 · cited 6×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
BackgroundInfluentialMiners, J. S., Morris, S., Love, S., & Kehoe, P. G. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2010-101395 · Cited by 30 · cited 3×
“Although it remains unproven that a decline in AAdegrading enzyme activity contributes to the accumulation of AA in AD (25, 26, 171), it is clear that overexpression of AA-degrading enzymes, neprilysin in particular, can reduce amyloid deposition and ameliorate cognitive decline in AD animal models (155, 161, 162).”
BackgroundSelf-citationMorelli, L., Llovera, R. E., Alonso, L. G., Frangione, B., Gay, G. D. P., Ghiso, J. A., & Castaño, E. M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.020 · Cited by 28 · cited 1×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
BackgroundMiners, J. S., Kehoe, P. G., & Love, S. (2007) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2007.12.003 · Cited by 28 · cited 3×
“We have optimized several immunocapture-based fluorogenic assays of AA-degrading enzyme activity for use on postmortem brain tissue and CSF (169, 170).”
MethodSelf-citationFuture Applications: Gene Therapy
Richardson, R. M., Varenika, V., Forsayeth, J. R., & Bankiewicz, K. S. (2009) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2009.04.004 · Cited by 25
Habisch, H., Schmid, B., Arnim, C. A. F. V., Ludolph, A. C., Brenner, R. E., & Storch, A. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0045 · Cited by 24 · cited 1×
“One in vitro study reported significant upregulation of NEP (692 T 226-fold increase of mRNA levels) after neuroectodermal conversion of adult mesenchymal stem cells (275).”
BackgroundDavenport, A. P., Kuc, R. E., & Mockridge, J. W. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199800001-00002 · Cited by 24
Burgos‐Ramos, E., Puebla‐Jiménez, L., & Arilla, E. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.11.019 · Cited by 21 · cited 2×
“Infusion of AA resulted in impaired SST signaling (230) and reduction in NEP (231).”
BackgroundImmunolocalisation of endothelin-1 in human brain
Naidoo, V., Naidoo, S., & Raidoo, D. M. (2004) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2004.03.007 · Cited by 21
Melzig, M. F., & Escher, F. (2002) · PubMed · Cited by 18
Wang, R., Wang, S., Malter, J. S., & Wang, D.-S. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1066 · Cited by 17 · cited 7×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
BackgroundInfluentialPrologue: Kinins and related systems. New life for old discoveries
Skidgel, R. A., Alhenc‐Gelas, F., & Campbell, W. B. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00164.2003 · Cited by 16
Nisemblat, Y., Belinson, H., Dolev, I., & Michaelson, D. M. (2008) · Neurodegenerative Diseases · doi:10.1159/000113692 · Cited by 11 · cited 1×
“However, these effects were much more modest than those observed after infusion of the metalloendopeptidase inhibitors, thiorphan and phosphoramidon, which produced a È30- to 50-fold increase in AA (45, 147), suggesting the existence of unidentified NEP-like endopeptidases (145).”
BackgroundLRP-1-mediated uptake of A beta by cerebrovascular smooth muscle cells: relationship to cytotoxicity
Ruzali, W. A. W., Kehoe, P. G., & Love, S. M. (2011) · Bristol Research (University of Bristol) · Cited by 1
Self-citation
Research works printed but not linked: 3
- 10.1042/bst0331101 · doi:10.1042/bst0331101 · Paper page
- 10.1097/64.5.378 · doi:10.1097/64.5.378
- 10.1097/62.9.885 · doi:10.1097/62.9.885
Cited by
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Self-citationMicroglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota
Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., et al. (2017) · Scientific Reports · doi:10.1038/srep41802 · Cited by 901
Microglial dysfunction in brain aging and Alzheimer's disease
Mosher, K. I., & Wyss-Coray, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.008 · Cited by 618
Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes
Katsuda, T., Tsuchiya, R., Kosaka, N., Yoshioka, Y., Takagaki, K., Oki, K., Takeshita, F., Sakai, Y., Kuroda, M., & Ochiya, T. (2013) · Scientific Reports · doi:10.1038/srep01197 · Cited by 565
Metadata
- Authors
- Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S.
- Affiliations
- Frenchay Hospital (GB)
- Corresponding author
- Miners, James Scott
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11
- Volume
- 70
- Issue
- 11
- Pages
- 944-959
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W1994344429
- Cited by
- 265
- References
- 287
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 14 · 2023: 15 · 2022: 14 · 2021: 11 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 23 · 2016: 32 · 2015: 14 · 2014: 31 · 2013: 24 · 2012: 20
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- Funders
- James Tudor Foundation
- Engineering and Physical Sciences Research Council (EP/G061866/1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid-beta, Alzheimer's disease, neprilysin, insulin-degrading enzyme, endothelin-converting enzyme, cathepsin B, cerebral amyloid angiopathy, amyloid clearance, convection-enhanced delivery, gene therapy, cognitive impairment
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Glycopeptides, Humans, Insulysin, Mice, Transgenic, Protease Inhibitors, Thiorphan, Neprilysin, Genetic Therapy, Amyloid beta-Peptides, Microglia, Stem Cell Transplantation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.